Leah Croll, MD, Assistant Professor of Clinical Neurology at the Lewis Katz School of Medicine at Temple University, offered insight to ABC News on phase III clinical trial results for Lecanemab, a monoclonal antibody that helps remove amyloid-beta clumps. The results, published in the New England Journal of Medicine, showed the medication slowed the rate of cognitive decline in participants in the early stages of Alzheimer’s disease. Dr. Croll was not involved in the study. Yahoo! News and MSN.com picked up the ABC News article.
Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.
myTempleHealth
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH